| Revision as of 11:05, 19 January 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers from ChemSpider, CommonChemistry and FDA for the Chem/Drugbox validation project - Updated: KEGG.← Previous edit |
Latest revision as of 20:14, 5 April 2024 edit undoحسن علي البط (talk | contribs)Extended confirmed users, Pending changes reviewers19,940 edits added Category:Heterocyclic compounds with 3 rings using HotCat |
| (39 intermediate revisions by 26 users not shown) |
| Line 1: |
Line 1: |
|
{{chembox |
|
{{chembox |
|
⚫ |
| verifiedrevid = 408765621 |
|
| Verifiedfields = changed |
|
|
⚫ |
| ImageFile=NBQX.svg |
| ⚫ |
| verifiedrevid = 400320626 |
|
|
⚫ |
| ImageSize= |
| ⚫ |
|ImageFile=NBQX.png |
|
|
|
| ImageFile1 = NBQX molecule spacefill.png |
| ⚫ |
|ImageSize= |
|
|
|
| ImageSize1 = 220 |
| ⚫ |
|IUPACName=2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzoquinoxaline -7-sulfonamide |
|
|
|
| ImageAlt1 = Space-filling model of the NBQX molecule |
| ⚫ |
|OtherNames= |
|
|
⚫ |
| PIN=6-Nitro-2,3-dioxo-1,2,3,4-tetrahydrobenzoquinoxaline-7-sulfonamide |
| ⚫ |
|Section1= {{Chembox Identifiers |
|
|
⚫ |
| OtherNames= |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
|
⚫ |
|Section1={{Chembox Identifiers |
|
|
| IUPHAR_ligand = 4264 |
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = 2521927 |
|
| ChemSpiderID = 2521927 |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = C13667 |
|
| KEGG = C13667 |
|
| InChI = 1/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22) |
|
| InChI = 1/C12H8N4O6S/c13-23(21,22)8-3-1-2-5-9(8)7(16(19)20)4-6-10(5)15-12(18)11(17)14-6/h1-4H,(H,14,17)(H,15,18)(H2,13,21,22) |
|
| InChIKey = UQNAFPHGVPVTAL-UHFFFAOYAI |
|
| InChIKey = UQNAFPHGVPVTAL-UHFFFAOYAI |
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|
| ChEMBL = 222519 |
|
| ChEMBL = 222519 |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| Line 18: |
Line 22: |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = UQNAFPHGVPVTAL-UHFFFAOYSA-N |
|
| StdInChIKey = UQNAFPHGVPVTAL-UHFFFAOYSA-N |
|
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
| CASNo=118876-58-7 |
|
| CASNo = 118876-58-7 |
| ⚫ |
| PubChem=3272524 |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| SMILES = (=O)c2cc3c(c1cccc(c12)S(=O)(=O)N)NC(=O)C(=O)N3 |
|
|
|
| UNII = 8LZ6Q43V2S |
|
⚫ |
| PubChem=3272524 |
|
⚫ |
| SMILES = (=O)c2cc3c(c1cccc(c12)S(=O)(=O)N)NC(=O)C(=O)N3 |
|
}} |
|
}} |
|
|Section2= {{Chembox Properties |
|
|Section2={{Chembox Properties |
|
| Formula=C<sub>12</sub>H<sub>8</sub>N<sub>4</sub>O<sub>6</sub>S |
|
| Formula=C<sub>12</sub>H<sub>8</sub>N<sub>4</sub>O<sub>6</sub>S |
|
| MolarMass=336.281 |
|
| MolarMass=336.281 |
|
| Appearance=brown/red powder |
|
| Appearance=brown/red powder |
|
| Density= |
|
| Density= |
|
| MeltingPt= |
|
| MeltingPt= |
|
| BoilingPt= |
|
| BoilingPt= |
|
| Solubility=Soluble to 100 mM in DMSO |
|
| Solubility=Soluble to 100 mM in DMSO |
|
}} |
|
}} |
|
|Section3= {{Chembox Hazards |
|
|Section3={{Chembox Hazards |
|
| MainHazards= |
|
| MainHazards= |
|
| FlashPt= |
|
| FlashPt= |
|
|
| AutoignitionPt = |
|
| Autoignition= |
|
|
}} |
|
}} |
|
}} |
|
}} |
| ⚫ |
'''NBQX''' (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzoquinoxaline-2,3-dione) is an ] ]. |
|
|
|
|
|
|
⚫ |
'''NBQX''' (2,3-dioxo-6-nitro-7-sulfamoyl-benzoquinoxaline) is an ] of the ]. |
| ⚫ |
NBQX blocks ]s in micromolar concentrations (~10–20 µmol) and also blocks kainate receptors. In experiments, it is used to counter ] ].<ref>Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". ''Nat Med.'' '''6''' (1): 67–70.</ref> NBQX was found to have anticonvulsant activity in rodent seizure models. <ref>Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. ''Epilepsy Res.'' '''15''':179–184.</ref> |
|
|
|
|
|
|
⚫ |
NBQX blocks AMPA receptors in micromolar concentrations (~10–20 μM) and also blocks ]s. In experiments, it is used to counter ] ].<ref>Pitt, D.; Werner, P.; Raine, C. S. (2000). "Glutamate excitotoxicity in a model of multiple sclerosis". ''Nat Med.'' '''6''' (1): 67–70.</ref> NBQX was found to have anticonvulsant activity in rodent seizure models.<ref>Yamaguchi, S.; Donevan, S.D.; Rogawski, M.A. (1993). Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models. ''Epilepsy Res.'' '''15''':179–184.</ref> |
| ⚫ |
As the disodium salt, NBQX is soluble in water at high concentrations (<30 mmol).{{Fact|date=August 2010}} |
|
|
|
|
|
⚫ |
As the disodium salt, NBQX is soluble in water at high concentrations (at least up to 100 mM). |
|
|
|
|
|
==See also== |
|
|
*] |
|
|
*] |
|
|
*] (MPQX) |
|
|
*] |
|
|
|
|
|
==References== |
|
==References== |
|
{{reflist}} |
|
{{Reflist}} |
|
|
|
|
|
|
{{Ionotropic glutamate receptor modulators}} |
|
{{Glutamate_receptor_ligands}} |
|
|
|
{{Glycine receptor modulators}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
|
{{biochem-stub}} |
|
{{biochem-stub}} |
|
|
|
|
] |
|